CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 6,280,000 shares, a decline of 16.2% from the July 15th total of 7,490,000 shares. Based on an average daily volume of 1,300,000 shares, the short-interest ratio is presently 4.8 days. Currently, 6.7% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CVAC shares. JMP Securities dropped their target price on shares of CureVac from $18.00 to $16.00 and set a “market outperform” rating on the stock in a research report on Friday. Leerink Partnrs downgraded shares of CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. Finally, SVB Leerink cut CureVac from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $12.00 to $4.00 in a research report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $9.33.

Hedge Funds Weigh In On CureVac

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CVAC. Ballentine Partners LLC acquired a new position in CureVac during the first quarter worth $38,000. Vontobel Holding Ltd. bought a new position in shares of CureVac in the 4th quarter valued at approximately $45,000. Bank of New York Mellon Corp acquired a new stake in CureVac in the 2nd quarter worth approximately $54,000. Vanguard Personalized Indexing Management LLC bought a new stake in CureVac during the fourth quarter worth approximately $68,000. Finally, International Assets Investment Management LLC acquired a new position in CureVac during the fourth quarter valued at approximately $71,000. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 0.3 %

CureVac stock traded down $0.01 during trading hours on Friday, hitting $3.24. The company had a trading volume of 517,596 shares, compared to its average volume of 999,556. CureVac has a fifty-two week low of $2.21 and a fifty-two week high of $9.59. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.25 and a quick ratio of 2.09. The firm has a market capitalization of $725.37 million, a P/E ratio of -2.44, a price-to-earnings-growth ratio of 1.87 and a beta of 2.64. The firm’s fifty day moving average is $3.48 and its 200-day moving average is $3.33.

CureVac (NASDAQ:CVAC) last issued its earnings results on Thursday, May 23rd. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.12). The firm had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. On average, research analysts forecast that CureVac will post 0.07 earnings per share for the current year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.